Orchestra BioMed Holdings, Inc.OBIO
What Orchestra BioMed Holdings, Inc. does.
Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies.
We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team.
Our flagship product candidates are Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of hypertension (“HTN”), the leading risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. We have an exclusive license and collaboration agreement with Medtronic, Inc. (an affiliate of Medtronic plc) (“Medtronic”) for the development and commercialization of AVIM Therapy for the treatment of uncontrolled HTN in patients indicated for a cardiac pacemaker (as amended, the “Medtronic Agreement”). We are actively conducting a double-blind, randomized, global pivotal study (the “BACKBEAT study”), enrolling up to 500 patients with uncontrolled hypertension who are indicated for a Medtronic dual-chamber pacemaker, with enrollment completion currently planned for mid-2026. We recently initiated patient enrollments in the Virtue SAB in the Treatment of Coronary In-Stent Restenosis (“ISR”) Trial (the “Virtue Trial”) for our U.S. investigational device exemption (“IDE”) pivotal study randomizing Virtue SAB vs. Boston Scientific Corporation’s AGENT™ drug-coated balloon. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll 740 patients in the United States with enrollment completion currently planned for mid-2027.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $3.5M | $2.8M | $2.6M | $33.5M |
| Net income | — | -$378,753 | -$33.6M | -$49.1M | -$61.0M | -$52.7M |
| Free cash flow | — | — | -$29.9M | -$46.2M | -$50.8M | -$49.5M |
More on OBIO.
- Orchestra BioMed Holdings, Inc. summary
- Orchestra BioMed Holdings, Inc. financial statements
- Orchestra BioMed Holdings, Inc. key metrics
- Orchestra BioMed Holdings, Inc. health scores and style box
- Orchestra BioMed Holdings, Inc. earnings
- Orchestra BioMed Holdings, Inc. dividends
- Orchestra BioMed Holdings, Inc. valuation
- Orchestra BioMed Holdings, Inc. ownership and insiders
- Orchestra BioMed Holdings, Inc. peers
Figures from Orchestra BioMed Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.